Annual Retained Earnings
-$384.86 M
-$21.49 M-5.91%
31 December 2023
Summary:
Lineage Cell Therapeutics annual retained earnings is currently -$384.86 million, with the most recent change of -$21.49 million (-5.91%) on 31 December 2023. During the last 3 years, it has fallen by -$90.78 million (-30.87%). LCTX annual retained earnings is now -38385.60% below its all-time high of -$1.00 million, reached on 30 June 1992.LCTX Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Retained Earnings
-$400.19 M
-$3.03 M-0.76%
30 September 2024
Summary:
Lineage Cell Therapeutics quarterly retained earnings is currently -$400.19 million, with the most recent change of -$3.03 million (-0.76%) on 30 September 2024. Over the past year, it has dropped by -$20.11 million (-5.29%). LCTX quarterly retained earnings is now -57070.29% below its all-time high of -$700.00 thousand, reached on 31 March 1992.LCTX Quarterly Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LCTX Retained Earnings Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -5.9% | -5.3% |
| 3 y3 years | -30.9% | -29.9% |
| 5 y5 years | -47.0% | -48.8% |
LCTX Retained Earnings High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -30.9% | at low | -29.9% | at low |
| 5 y | 5 years | -47.0% | at low | -48.8% | at low |
| alltime | all time | <-9999.0% | at low | <-9999.0% | at low |
Lineage Cell Therapeutics Retained Earnings History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | -$400.19 M(+0.8%) |
| June 2024 | - | -$397.16 M(+1.5%) |
| Mar 2024 | - | -$391.40 M(+1.7%) |
| Dec 2023 | -$384.86 M(+5.9%) | -$384.86 M(+1.3%) |
| Sept 2023 | - | -$380.08 M(+1.9%) |
| June 2023 | - | -$372.97 M(+1.4%) |
| Mar 2023 | - | -$367.74 M(+1.2%) |
| Dec 2022 | -$363.37 M(+7.8%) | -$363.37 M(+1.8%) |
| Sept 2022 | - | -$357.02 M(+1.7%) |
| June 2022 | - | -$350.95 M(+2.0%) |
| Mar 2022 | - | -$344.18 M(+2.1%) |
| Dec 2021 | -$337.10 M(+14.6%) | -$337.10 M(+9.4%) |
| Sept 2021 | - | -$308.11 M(+2.6%) |
| June 2021 | - | -$300.28 M(+1.6%) |
| Mar 2021 | - | -$295.49 M(+0.5%) |
| Dec 2020 | -$294.08 M(+7.6%) | -$294.08 M(-0.7%) |
| Sept 2020 | - | -$296.10 M(+2.7%) |
| June 2020 | - | -$288.34 M(+2.3%) |
| Mar 2020 | - | -$281.82 M(+3.1%) |
| Dec 2019 | -$273.42 M(+4.4%) | -$273.42 M(+1.7%) |
| Sept 2019 | - | -$268.94 M(+6.5%) |
| June 2019 | - | -$252.44 M(+13.5%) |
| Mar 2019 | - | -$222.40 M(-15.1%) |
| Dec 2018 | -$261.86 M(+21.1%) | -$261.86 M(+20.7%) |
| Sept 2018 | - | -$216.91 M(-23.5%) |
| June 2018 | - | -$283.63 M(+1.5%) |
| Mar 2018 | - | -$279.42 M(+29.2%) |
| Dec 2017 | -$216.30 M(+10.2%) | -$216.30 M(+49.8%) |
| Sept 2017 | - | -$144.36 M(-9.0%) |
| June 2017 | - | -$158.68 M(+7.9%) |
| Mar 2017 | - | -$147.03 M(-25.1%) |
| Dec 2016 | -$196.32 M(-14.6%) | -$196.32 M(+3.0%) |
| Sept 2016 | - | -$190.53 M(-14.1%) |
| June 2016 | - | -$221.74 M(-10.0%) |
| Mar 2016 | - | -$246.29 M(+7.1%) |
| Dec 2015 | -$229.89 M(+26.2%) | -$229.89 M(+6.6%) |
| Sept 2015 | - | -$215.76 M(+6.8%) |
| June 2015 | - | -$202.06 M(+5.0%) |
| Mar 2015 | - | -$192.36 M(+5.6%) |
| Dec 2014 | -$182.19 M(+25.0%) | -$182.19 M(+6.2%) |
| Sept 2014 | - | -$171.61 M(+5.0%) |
| June 2014 | - | -$163.39 M(+6.2%) |
| Mar 2014 | - | -$153.88 M(+5.6%) |
| Dec 2013 | -$145.78 M(+43.1%) | -$145.78 M(+15.5%) |
| Sept 2013 | - | -$126.17 M(+7.7%) |
| June 2013 | - | -$117.18 M(+6.9%) |
| Mar 2013 | - | -$109.61 M(+7.6%) |
| Dec 2012 | -$101.90 M(+26.6%) | -$101.90 M(+6.3%) |
| Sept 2012 | - | -$95.86 M(+5.5%) |
| June 2012 | - | -$90.90 M(+6.4%) |
| Mar 2012 | - | -$85.44 M(+6.2%) |
| Dec 2011 | -$80.47 M(+25.8%) | -$80.47 M(+7.1%) |
| Sept 2011 | - | -$75.11 M(+4.9%) |
| June 2011 | - | -$71.60 M(+6.4%) |
| Mar 2011 | - | -$67.32 M(+5.3%) |
| Dec 2010 | -$63.95 M(+21.2%) | -$63.95 M(+4.9%) |
| Sept 2010 | - | -$60.98 M(+8.3%) |
| June 2010 | - | -$56.32 M(+4.2%) |
| Mar 2010 | - | -$54.06 M(+2.4%) |
| Dec 2009 | -$52.77 M(+10.8%) | -$52.77 M(-2.6%) |
| Sept 2009 | - | -$54.19 M(+7.1%) |
| June 2009 | - | -$50.62 M(+3.0%) |
| Mar 2009 | - | -$49.14 M(+3.2%) |
| Dec 2008 | -$47.63 M | -$47.63 M(+3.4%) |
| Sept 2008 | - | -$46.06 M(+2.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2008 | - | -$44.98 M(+1.5%) |
| Mar 2008 | - | -$44.32 M(+1.1%) |
| Dec 2007 | -$43.84 M(+3.4%) | -$43.84 M(+0.8%) |
| Sept 2007 | - | -$43.52 M(+0.5%) |
| June 2007 | - | -$43.30 M(+0.8%) |
| Mar 2007 | - | -$42.96 M(+1.3%) |
| Dec 2006 | -$42.41 M(+4.6%) | -$42.41 M(+0.9%) |
| Sept 2006 | - | -$42.03 M(+0.8%) |
| June 2006 | - | -$41.69 M(+1.6%) |
| Mar 2006 | - | -$41.02 M(+1.2%) |
| Dec 2005 | -$40.54 M(+5.4%) | -$40.54 M(+1.2%) |
| Sept 2005 | - | -$40.05 M(+1.0%) |
| June 2005 | - | -$39.64 M(+1.1%) |
| Mar 2005 | - | -$39.19 M(+1.9%) |
| Dec 2004 | -$38.47 M(+8.7%) | -$38.47 M(+1.4%) |
| Sept 2004 | - | -$37.92 M(+1.2%) |
| June 2004 | - | -$37.47 M(+1.2%) |
| Mar 2004 | - | -$37.02 M(+4.6%) |
| Dec 2003 | -$35.38 M(+5.2%) | -$35.38 M(+1.7%) |
| Sept 2003 | - | -$34.78 M(-1.0%) |
| June 2003 | - | -$35.15 M(+2.2%) |
| Mar 2003 | - | -$34.39 M(+2.2%) |
| Dec 2002 | -$33.64 M(+9.2%) | -$33.64 M(+2.4%) |
| Sept 2002 | - | -$32.86 M(+1.8%) |
| June 2002 | - | -$32.28 M(+2.5%) |
| Mar 2002 | - | -$31.50 M(+2.3%) |
| Dec 2001 | -$30.80 M(+13.5%) | -$30.80 M(+2.3%) |
| Sept 2001 | - | -$30.11 M(+3.1%) |
| June 2001 | - | -$29.21 M(+4.0%) |
| Mar 2001 | - | -$28.09 M(+3.5%) |
| Dec 2000 | -$27.14 M(+22.2%) | -$27.14 M(+4.0%) |
| Sept 2000 | - | -$26.09 M(+4.9%) |
| June 2000 | - | -$24.86 M(+5.7%) |
| Mar 2000 | - | -$23.53 M(+5.9%) |
| Dec 1999 | -$22.21 M(+33.0%) | -$22.21 M(+6.8%) |
| Sept 1999 | - | -$20.80 M(+12.4%) |
| June 1999 | - | -$18.50 M(+5.7%) |
| Mar 1999 | - | -$17.50 M(+10.8%) |
| Dec 1998 | -$16.70 M(+14.4%) | - |
| Sept 1998 | - | -$15.80 M(+8.2%) |
| June 1998 | - | -$14.60 M(+5.0%) |
| June 1998 | -$14.60 M(+30.4%) | - |
| Mar 1998 | - | -$13.90 M(+8.6%) |
| Dec 1997 | - | -$12.80 M(+4.9%) |
| Sept 1997 | - | -$12.20 M(+8.9%) |
| June 1997 | -$11.20 M(+38.3%) | -$11.20 M(+10.9%) |
| Mar 1997 | - | -$10.10 M(+5.2%) |
| Dec 1996 | - | -$9.60 M(+9.1%) |
| Sept 1996 | - | -$8.80 M(+8.6%) |
| June 1996 | -$8.10 M(+32.8%) | -$8.10 M(+24.6%) |
| Sept 1995 | - | -$6.50 M(+6.6%) |
| June 1995 | -$6.10 M(+64.9%) | -$6.10 M(+13.0%) |
| Mar 1995 | - | -$5.40 M(+10.2%) |
| Dec 1994 | - | -$4.90 M(+16.7%) |
| Sept 1994 | - | -$4.20 M(+13.5%) |
| June 1994 | -$3.70 M(+68.2%) | -$3.70 M(+12.1%) |
| Mar 1994 | - | -$3.30 M(+13.8%) |
| Dec 1993 | - | -$2.90 M(+31.8%) |
| Sept 1993 | - | -$2.20 M(0.0%) |
| June 1993 | -$2.20 M(+120.0%) | -$2.20 M(+15.8%) |
| Mar 1993 | - | -$1.90 M(+18.8%) |
| Dec 1992 | - | -$1.60 M(+23.1%) |
| Sept 1992 | - | -$1.30 M(+30.0%) |
| June 1992 | -$1.00 M | -$1.00 M(+42.9%) |
| Mar 1992 | - | -$700.00 K |
FAQ
- What is Lineage Cell Therapeutics annual retained earnings?
- What is the all time high annual retained earnings for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics annual retained earnings year-on-year change?
- What is Lineage Cell Therapeutics quarterly retained earnings?
- What is the all time high quarterly retained earnings for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics quarterly retained earnings year-on-year change?
What is Lineage Cell Therapeutics annual retained earnings?
The current annual retained earnings of LCTX is -$384.86 M
What is the all time high annual retained earnings for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high annual retained earnings is -$1.00 M
What is Lineage Cell Therapeutics annual retained earnings year-on-year change?
Over the past year, LCTX annual retained earnings has changed by -$21.49 M (-5.91%)
What is Lineage Cell Therapeutics quarterly retained earnings?
The current quarterly retained earnings of LCTX is -$400.19 M
What is the all time high quarterly retained earnings for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high quarterly retained earnings is -$700.00 K
What is Lineage Cell Therapeutics quarterly retained earnings year-on-year change?
Over the past year, LCTX quarterly retained earnings has changed by -$20.11 M (-5.29%)